Digital Asset Acquisition Corp. (DAAQ): Entry into a Material Definitive Agreement

MapLight Therapeutics (MPLT) priced a $150 million PIPE, selling 9.2M shares at $11.38 and 4.0M pre-funded warrants at $11.3799, exercisable at $0.0001 with no expiration. Proceeds will fund CNS drug ML-007C-MA, including VISTA Phase 2 in Alzheimer’s disease psychosis and ZEPHYR-2 Phase 3 in schizophrenia. Closing expected Aug. 14, 2026.

Tyson Foods said it will close or sell three US beef facilities, ending operations at Joslin, Illinois and Eagle Mountain, Utah, and pursuing the sale of Pasco, Washington, while shifting capacity to other sites. The move follows prior Tyson beef shutdowns and comes as a 75-year cattle supply trough drives losses. Tyson forecast a $500m to $650m adjusted beef operating loss for fiscal 2026.

MicroVision (NASDAQ:MVIS) said it has commenced a proposed public offering of units, each unit consisting of one share of common stock (or a pre-funded warrant in lieu) and one warrant to buy one share. MicroVision will sell the shares and warrants, with final terms to be set at pricing. Net proceeds are for general corporate purposes, including working capital and capex.

Oracle plans another layoff round in August 2026, according to Business Insider citing internal documents and people familiar with the plans. It says some teams could face double-digit cuts, with managers asked to identify affected employees ahead of Sept. 1. Oracle previously cut 21,000 jobs and recorded $1.8B restructuring charges. Oracle is funding AI data centers with large debt and equity.

Tyson Foods said it will close its Joslin, Illinois beef plant and its Eagle Mountain, Utah case-ready facility, and is pursuing the sale of its Pasco, Washington beef facility, citing strategic changes to its beef network amid a “historic” cattle shortage. Tyson plans to shift capacity to Dakota City, Nebraska; Holcomb, Kansas; and Amarillo, Texas, and ramp a second shift in Amarillo, according to the company.

Karyopharm Therapeutics reported Q2 results showing a $67 million loss and cash reserves of $65.4 million. A $15.8 million loan payment is due Sept. 10, and without financing or a waiver the company says it would breach a $10.0 million liquidity covenant and could default. It is negotiating with lenders and pursuing Xpovio label expansion; Q2 Xpovio sales were $30.8 million.